Atticus in the News
Atticus Pharma is a therapeutics company developing drugs for immunodermatology and associated diseases. Our two initial programs are for the treatment of cutaneous lupus lesions and androgenic alopecia. Atticus licensed from Zylö Therapeutics the Z-pod® sustained-release technology that originated at Albert Einstein College of Medicine that was further developed at Zylö. The technology provides a depot-like effect and enables delivery of therapeutic agents (small molecules, peptides, siRNA) in a sustained-release manner. Some of the news items listed below were issued by Zylö prior to the license being forged, but relate to Atticus and its various programs.
Atticus Initiates Clinical Study for ATC-002 in Androgenic Alopecia
GREENVILLE - (EIN Presswire) - April 14, 2025. Atticus Pharma Inc, a therapeutics company focused on immunodermatology and associated conditions, today announced the initiation of a human clinical study of ATC-002 in androgenic alopecia. ATC-002 is a proprietary product candidate that delivers a mitochondrial-activating molecule using Atticus’s Z-pod sustained-release technology. Several subjects have been screened and have received ATC-002.
Atticus accepted into NYU's Endless Frontier Labs [EFL] Mentorship Program
Only 78 of over 1,400 applicants accepted into this prestigious program that is designed to optimize each startup’s chance of scaling into a successful company.
